tbuckley/cabot-search huggingface dataset:
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
Authors: Chenghuan Song, Jiyun Shi, Pingao Zhang, Yongfang Zhang, Jianrong Xu, Lanxue Zhao, Rui Zhang, Hao Wang, Hongzhuan Chen
Journal: Translational Neurodegeneration (2022)

Alzheimer's disease (AD) is the most common neurodegenerative disease in the elderly worldwide. However, the complexity of AD pathogenesis leads to discrepancies in the understanding of this disease, and may be the main reason for the failure of AD drug development. Fortunately, many ongoing preclinical and clinical studies will continually open up avenues to unravel disease mechanisms and guide strategies for AD diagnosis and drug development. For example, immunotherapeutic strategies targeting amyloid-β (Aβ) and tau proteins were once deemed almost certainly effective in clinical treatment due to the excellent preclinical results. However, the repeated failures of clinical trials on vaccines and humanized anti-Aβ and anti-tau monoclonal antibodies have resulted in doubts on this strategy. Recently, a new anti-Aβ monoclonal antibody (Aducanumab) has been approved by the US Food and Drug Administration, which brings us back to the realization that immunotherapy strategies targeting Aβ may be still promising. Meanwhile, immunotherapies based on other targets such as tau, microglia and gut-brain axis are also under development. Further research is still needed to clarify the forms and epitopes of targeted proteins to improve the accuracy and effectiveness of immunotherapeutic drugs. In this review, we focus on the immunotherapies based on Aβ, tau and microglia and their mechanisms of action in AD. In addition, we present up-to-date advances and future perspectives on immunotherapeutic strategies for AD.
THIRTY-DAY READMISSION RATE OF SAME-DAY DISCHARGE PROTOCOL FOLLOWING LEFT ATRIAL APPENDAGE OCCLUSION: A PROPENSITY SCORE-MATCHED ANALYSIS FROM NATIONAL READMISSION DATABASE
Authors: Iwanari Kawamura, Toshiki Kuno, Alexandros Briasoulis, Aaqib Malik
Journal: Journal of the American College of Cardiology (2022)
SAFETY AND FEASIBILITY OF TRANSCAVAL APPROACH FOR TRANSCATHETER AORTIC VALVE REPLACEMENTS
Authors: Ahmed Kazem, Mustafa Mohammed, Michael Chiang, Pedro Engel Gonzales, Tiberio M. Frisoli, Pedro Arturo Villablanca, James Chihong Lee, Dee Dee Wang, Janet Fredal Wyman, Brian O’Neill, William W. O’Neill, Marvin H. Eng
Journal: Journal of the American College of Cardiology (2022)
SEVERE MITRAL REGURGITATION WITH ACCESSORY MITRAL VALVE TISSUE IN SYMPTOMATIC PATIENT WITHOUT SIGNIFICANT LVOT OBSTRUCTION
Authors: Bradley Casey, Mustanser Badar, Thanh Dinh Hoang, Haitham Mazek, William Sanchez-Garcia, Amudhan Jyothidasan, Manoj Bhandari
Journal: Journal of the American College of Cardiology (2022)
PI3Kδ/γ inhibitor BR101801 extrinsically potentiates effector CD8<sup>+</sup>T cell-dependent antitumor immunity and abscopal effect after local irradiation
Authors: Yi Na Yoon, Eunju Lee, Young-Ju Kwon, Jeong-An Gim, Tae-Jin Kim, Jae-Sung Kim
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background Radiotherapy enhances antitumor immunity. However, it also induces immunosuppressive responses, which are major hurdles for an effective treatment. Thus, targeting the immunosuppressive tumor microenvironment is essential for enhancing the antitumor immunity after radiotherapy. Retrospective studies show that a blockade of PI3Kδ and/or γ, which are abundant in leukocytes, exhibits antitumor immune response by attenuating activity of immune suppressive cells, however, the single blockade of PI3Kδ or γ is not sufficient to completely eliminate solid tumor. Methods We used BR101801, PI3Kδ/γ inhibitor in the CT-26 syngeneic mouse model with a subcutaneously implanted tumor. BR101801 was administered daily, and the target tumor site was locally irradiated. We monitored the tumor growth regularly and evaluated the immunological changes using flow cytometry, ELISpot, and transcriptional analysis. Results This study showed that BR101801 combined with irradiation promotes systemic antitumor immunity and abscopal response by attenuating the activity of immune suppressive cells in the CT-26 tumor model. BR101801 combined with irradiation systemically reduced the proliferation of regulatory T cells (Tregs) and enhanced the number of tumor-specific CD8α + T cells in the tumor microenvironment, thereby leading to tumor regression. Furthermore, the high ratio of CD8α + T cells to Tregs was maintained for 14 days after irradiation, resulting in remote tumor regression in metastatic lesions, the so-called abscopal effect. Moreover, our transcriptomic analysis showed that BR101801 combined with irradiation promoted the immune-stimulatory tumor microenvironment, suggesting that the combined therapy converts immunologically cold tumors into hot one. Conclusions Our data suggest the first evidence that PI3Kδ/γ inhibition combined with irradiation promotes systemic antitumor immunity against solid tumors, providing the preclinical result of the potential use of PI3Kδ/γ inhibitor as an immune-regulatory radiosensitizer.
Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D)
Authors: John P. Kirwan, Anita P. Courcoulas, David E. Cummings, Allison B. Goldfine, Sangeeta R. Kashyap, Donald C. Simonson, David E. Arterburn, William F. Gourash, Ashley H. Vernon, John M. Jakicic, Mary Elizabeth Patti, Kathy Wolski, Philip R. Schauer
Journal: Diabetes Care (2022)

OBJECTIVE The overall aim of the Alliance of Randomized Trials of Medicine versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D) consortium is to assess the durability and longer-term effectiveness of metabolic surgery compared with medical/lifestyle management in patients with type 2 diabetes (NCT02328599). RESEARCH DESIGN AND METHODS A total of 316 patients with type 2 diabetes previously randomly assigned to surgery (N = 195) or medical/lifestyle therapy (N = 121) in the STAMPEDE, TRIABETES, SLIMM-T2D, and CROSSROADS trials were enrolled into this prospective observational cohort. The primary outcome was the rate of diabetes remission (hemoglobin A1c [HbA1c] ≤6.5% for 3 months without usual glucose-lowering therapy) at 3 years. Secondary outcomes included glycemic control, body weight, biomarkers, and comorbidity reduction. RESULTS Three-year data were available for 256 patients with mean 50 ± 8.3 years of age, BMI 36.5 ± 3.6 kg/m2, and duration of diabetes 8.8 ± 5.7 years. Diabetes remission was achieved in more participants following surgery than medical/lifestyle intervention (60 of 160 [37.5%] vs. 2 of 76 [2.6%], respectively; P &amp;lt; 0.001). Reductions in HbA1c (Δ = −1.9 ± 2.0 vs. −0.1 ± 2.0%; P &amp;lt; 0.001), fasting plasma glucose (Δ = −52 [−105, −5] vs. −12 [−48, 26] mg/dL; P &amp;lt; 0.001), and BMI (Δ = −8.0 ± 3.6 vs. −1.8 ± 2.9 kg/m2; P &amp;lt; 0.001) were also greater after surgery. The percentages of patients using medications to control diabetes, hypertension, and dyslipidemia were all lower after surgery (P &amp;lt; 0.001). CONCLUSIONS Three-year follow-up of the largest cohort of randomized patients followed to date demonstrates that metabolic/bariatric surgery is more effective and durable than medical/lifestyle intervention in remission of type 2 diabetes, including among individuals with class I obesity, for whom surgery is not widely used.
Radioactive Iodine: Recognizing the Need for Risk-Benefit Balance
Authors: Andrew M. McDonald, Brenessa Lindeman, Deepti Bahl
Journal: Journal of Clinical Oncology (2022)

Salivary glands (> 1,000 mGy)RR: 1.34 (0.86-2.09)Lungs (100-499 mGy) RR: 1.42 (0.97-2.08)Stomach (> 1,000 mGy) RR: 1.61 (0.7-3.69) Kidneys (> 1,000 mGy) RR: 1.34 (0.86-2.09)Prostate (100-499 mGy) RR: 1.36 (0.91-2.04)Breast (100-499 mGy) RR: 1.18 (0.99-1.40)Colon and rectum (500-999 mGy) RR: 1.28 (0.86-1.89)Uterus (100-499 mGy) RR: 1.55 (1.03-2.32)FIG 1. Locations of solid tumors with highest RR of developing a solid malignancy after radioactive iodine for differentiated thyroid cancer.Absorbed dose to each organ given in italics.RR, relative risk.
THE RELATIONSHIP BETWEEN ASCVD RISK, INFLAMMATION, AND CORONARY MICROVASCULAR DYSFUNCTION IN RHEUMATOID ARTHRITIS
Authors: Brittany Weber, Dana Weisenfeld, Thany Seyok, Sicong S. Huang, Elena Massarotti, Leanne Barrett, Courtney Foster Bibbo, Dan Solomon, Jorge Plutzky, Marcy Bolster, Marcelo F. Di Carli, Katherine P. Liao
Journal: Journal of the American College of Cardiology (2022)
SERUM BIOMARKERS AND AMYLOID BURDEN BY LEFT VENTRICULAR EXTRACELLULAR VOLUME PREDICT ADVERSE OUTCOMES IN LIGHT CHAIN AMYLOIDOSIS
Authors: Olivier Clerc, Sarah Cuddy, Alexandra Taylor, Michael Jerosch-Herold, Shivani Rao, Marie F. Kijewski, Frederick L. Ruberg, Marcelo F. Di Carli, Ronglih Liao, Rodney H. Falk, Raymond Y. Kwong, Sharmila Dorbala
Journal: Journal of the American College of Cardiology (2022)
COVID-19–Associated cardiac pathology at the postmortem evaluation: a collaborative systematic review
Authors: Raghed Almamlouk, Tarek Kashour, Sawsan Obeidat, Melanie C. Bois, Joseph J. Maleszewski, Osama A. Omrani, Rana Tleyjeh, Elie Berbari, Zaher Chakhachiro, Bassel Zein-Sabatto, Dana Gerberi, Imad M. Tleyjeh, Alberto E. Paniz Mondolfi, Aloke V. Finn, Amaro Nunes Duarte-Neto, Amy V. Rapkiewicz, Andrea Frustaci, Arthur-Atilla Keresztesi, Brian Hanley, Bruno Märkl, Christelle Lardi, Clare Bryce, Diana Lindner, Diego Aguiar, Dirk Westermann, Edana Stroberg, Eric J. Duval, Esther Youd, Gaetano Pietro Bulfamante, Isabelle Salmon, Johann Auer, Joseph J. Maleszewski, Klaus Hirschbühl, Lara Absil, Lisa M. Barton, Luiz Fernando Ferraz da Silva, Luiza Moore, Marisa Dolhnikoff, Martin Lammens, Melanie C. Bois, Michael Osborn, Myriam Remmelink, Paulo Hilario Nascimento Saldiva, Philippe G. Jorens, Randall Craver, Renata Aparecida de Almeida Monteiro, Roberto Scendoni, Sanjay Mukhopadhyay, Tadaki Suzuki, Thais Mauad, Tony Fracasso, Zachary Grimes
Journal: Clinical Microbiology and Infection (2022)
Corrigendum to ‘Guidance on the management of left ventricular assist device (<scp>LVAD</scp>) supported patients for the <scp>non‐LVAD</scp> specialist healthcare provider: executive summary [<i>Eur J Heart Fail</i> 2021;23:1597–1609]
Authors: Tuvia Gal, Ben Avraham, Davor Milicic, Marisa Crespo-Leiro, Andrew Coats, Giuseppe Rosano, Petar Seferovic, Frank Ruschitzka, Marco Metra, Stefan Anker, Gerasimos Filippatos, Johann Altenberger, Stamatis Adamopoulos, Yaron Barac, Ovidiu Chioncel, Nicolaas De Jonge, Jeremy Elliston, Maria Frigerio, Eva Goncalvesova, Israel Gotsman, Avishai Grupper, Righab Hamdan, Yoav Hammer, Tal Hasin, Loreena Hill, Osnat Itzhaki, Ben Zadok, Miriam Abuhazira, Jacob Lavee, Wilfried Mullens, Sanem Nalbantgil, Massimo Piepoli, Piotr Ponikowski, Luciano Potena, Arsen Ristic, Arjang Ruhparwar, Aviv Shaul, Laurens Tops, Steven Tsui, Tiny Jaarsma, Finn Gustafsson, Giuseppe Rosano'
Journal: European Journal of Heart Failure (2022)
CARDIAC MAGNETIC RESONANCE (CMR) FINDINGS IN PATIENTS WITH ACUTE MYOCARDITIS AFTER RECEIVING THE SECOND DOSE OF COVID19 MRNA VACCINE: A SYSTEMATIC REVIEW
Authors: Lina Alatta, Leina Elomeiri, Samah Yousif, Mazin Ali, Osama Ahmed, Sarah Elsayed, Nadir G. Abdelrahman, Senthil Thambidorai
Journal: Journal of the American College of Cardiology (2022)
Systematic reviews and meta-analyses in animal model research: as necessary, and with similar pros and cons, as in patient research
Authors: Ramon Farré, Miguel A. Martínez-García, David Gozal
Journal: European Respiratory Journal (2022)

Systematic reviews and meta-analyses (SRMAs) are very useful tools for evaluating the status of research on a given topic in medical sciences [1, 2]. Although SRMAs are primarily used in clinical investigation, the methodologies underlying SRMAs can also be readily used to assess extant data focused on research in animal models of disease [3]. Systematic reviews and meta-analyses from research data in animal models of disease are useful for translational medicine <https://bit.ly/3kOvVUN>
Abstract P5-15-05: Influence of shared decision making with decision aids on decisional conflict and regret in breast cancer surgery: A randomized controlled trial
Authors: Ka-Wai Tam, Shi-Qian Lin
Journal: Cancer Research (2022)

Abstract Background: Patients with breast cancer usually encounter difficulties in making treatment decisions. Shared decision making (SDM) is a way to minimize decisional conflicts of patients, and patients’ decision aids (PDAs) have been developed to support the implementation of SDM. However, the effect of PDAs in Asia is inconclusive. Therefore, we developed a randomized controlled trial to evaluate the effect of SDM assisted by PDAs on decisional conflict among patients with breast cancer in Taiwan. Methods: This is a two-group, outcome assessor-blind, randomized, controlled trial. A total of 151 patients diagnosed with breast cancer were assigned to the PDAs group or the classic group. Demographic and clinical variables were analyzed to identify the variables influencing the treatment choice. The patients’ decision-making difficulties were evaluated using the 4-item SURE scale during the pre-operative hospitalization, and the decisional conflicts were assessed by the 5-item Decision Regret scale and Hospital Anxiety and Depression Scale (HADS) at one month postoperatively.Results: The choice of breast conservation therapy and mastectomy was not significantly different between the PDA and classic groups. Compared with the classic group, patients in PDA group had more depression after making decision (P = 0.029). No significant difference was noted in terms of the total scores in the SURE scale and Decision Regret scale between the groups.Conclusions: Our study revealed that PDA did not assist breast cancer patients in decision making. Clinicians should focus on SDM based on evidence-based medicine with care, and help patients taking their individual preference into consideration. Citation Format: Ka-Wai Tam, Shi-Qian Lin. Influence of shared decision making with decision aids on decisional conflict and regret in breast cancer surgery: A randomized controlled trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P5-15-05.
Error in Figure Legends
Journal: JAMA Neurology (2022)

Yen Ying Lim, PhD; Paul Maruff, PhD; Nicolas R. Barthélemy, PhD; Alison Goate, PhD; Jason Hassenstab, PhD; Chihiro Sato, PhD; Anne M. Fagan, PhD; Tammie L. S. Benzinger, PhD; Chengjie Xiong, PhD; Carlos Cruchaga, PhD; Johannes Levin, PhD; Martin R. Farlow, MD, PhD; Neill R. Graff-Radford, MD, PhD; Christoph Laske, PhD; Colin L. Masters, MD; Stephen Salloway, MD, PhD; Peter R. Schofield, PhD; John C. Morris, MD, PhD; Randall J. Bateman, MD, PhD; Eric McDade, MD, PhD; Dominantly Inherited Alzheimer Network; Jasmeer Chhatwal; Colleen Fitzpatrick; Courtney Bodge; Stephen Salloway; Chrismary De La Cruz; Jill Goldman; Arlene Mejia; Katie Neimeyer; James Noble; Samantha Gardener; Ralph Martins; Hamid Sohrabi; Kevin Taddei; Kathleen Carter; Duc Duong; Erik Johnson; Allan Levey; Lingyan Ping; Nick Seyfried; Susanne Gräber-Sultan; Lisa Häsler; Anna Hofmann; Mathias Jucker; Stephan Käser; Elke Kuder-Buletta; Christoph Laske; Oliver Preische; Anna Diffenbacher; Yakushev Igor; Johannes Levin; Jonathan Vöglein; Ulricke Obermüller; Bianca Esposito; Alison Goate; Alan Renton; Jared Brosch; Jill Buck; Marty Farlow; Bernardino Ghetti; Ricardo Allegri; Patricio Chrem; Noelia Egido; Christian Haass; Estrella Morenas-Rodriguez; Brigitte Nuscher; Gregory S Day; Neill Graff-Radford; Morgan Graham; Sochenda Stephens; Clifford Jack; Jacob Bechara; William (Bill) Brooks; Peter Schofield; Aki Araki; Takeshi Ikeuchi; Kensaku Kasuga; Kenji Ishii; Hisako Fujii; Michio Senda; Hiroyuki Shimada; Ryoko Ihara; Akemi Nagamatsu; Yoshiki Niimi; Jane Douglas; Nick Fox; Miguel Grilo; Cath Mummery; Antoinette O'Connor; Colin Masters; Robert Koeppe; Sarah Berman; Sarah Goldberg; Snezana Ikonomovic; William (Bill) Klunk; Oscar Lopez; James Mountz; Neelesh Nadkarni; Riddhi Patira; Lori Smith; Beth Snitz; Sarah Thompson; Elise Weamer; Neal Scott Mason; Helena Chui; John Ringman; Sarah Adams; Nicolas Barthelemy; Randall Bateman; Tammie Benzinger; Susan Brandon; Virginia Buckles; Lisa Cash; Charlie Chen; Jasmin Chua; Carlos Cruchaga; Darcy Denner; Aylin Dincer; Tamara Donahue; Anne Fagan; Becca Feldman; Shaney Flores; Erin Franklin; Nelly Friedrichsen; Alyssa Gonzalez; Brian Gordon; Julia Gray; Emily Gremminger; Alex Groves; Jason Hassenstab; Cortaiga Hellm; Elizabeth Herries; Laura Hoechst-Swisher; David Holtzman; Russ Hornbeck; Gina Jerome; Celeste Karch; Sarah Keefe; Deb Koudelis; Yan Li; Jacob Marsh; Rita Martinez; Kwasi Mawuenyega; Austin McCullough; Eric McDade; John Morris; Joanne Norton; Richard Perrin; Kristine Shady; Wendy Sigurdson; Jennifer Smith; Peter Wang; Qing Wang; Chengjie Xiong; Jinbin Xu; Xiong Xu
Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
Authors: Vicky C. Chang, Ali A. Khan, Wen-Yi Huang, Hormuzd A. Katki, Mark P. Purdue, Ola Landgren, Jonathan N. Hofmann
Journal: Blood Cancer Journal (2022)

a Number of participants with non-IgM MGUS that did not progress to MM. b Number of participants with non-IgM MGUS that progressed to MM. c Adjusted for sex (overall model only), age, age 2 , race (non-Hispanic white, non-Hispanic Black, other [Hispanic, Asian, and Pacific Islander]), study center (Upper Midwest [Wisconsin and Minnesota], West/South [Colorado, Hawaii, Missouri, Utah, and Alabama], East [Georgetown, Detroit, and Pittsburgh]), and calendar year of blood draw (1995-2000, 2001-2002, 2003-2006).d Adjusted for variables in the basic model and additionally for immunoglobulin isotype (IgA, IgG, biclonal), elevated M-protein concentration (no, yes [≥15 g/ L]), serum free light-chain ratio (normal [0.26-1.65],abnormal [<0.26 or >1.65]), and immunoparesis (number of uninvolved immunoglobulins below the lower level of the normal reference range; none, 1, 2, biclonal).e P for multiplicative interaction between sex and continuous BMI = 0.15 (basic model) and 0.61 (full model).
TRENDS IN UPTAKE AND HOSPITAL-LEVEL VARIABILITY OF DIRECT ORAL ANTICOAGULANTS FOR PATIENTS WITH ATRIAL FIBRILLATION: A NATIONWIDE ANALYSIS OF 432,536 PATIENTS
Authors: Ahmed A. Kolkailah, Ann Marie Navar, Robert Overton, Nishant Shah, Justin Rousseau, Greg C. Flaker, Michael Pignone, Eric D. Peterson
Journal: Journal of the American College of Cardiology (2022)
Exosomes in multiple myeloma: from bench to bedside
Authors: Eline Menu, Karin Vanderkerken
Journal: Blood (2022)

Multiple myeloma (MM) remains an incurable plasma cell malignancy that develops in the bone marrow (BM). This BM is partially responsible for protecting the MM cells against current standard-of-care therapies and for accommodating MM-related symptoms such as bone resorption and immune suppression. Increasing evidence has implicated extracellular vesicles (EV), including exosomes in the different processes within the BM. Exosomes are <150-nm-sized vesicles secreted by different cell types including MM cells. These vesicles contain protein and RNA cargo that they deliver to the recipient cell. In this way, they have been implicated in MM-related processes including osteolysis, angiogenesis, immune suppression, and drug resistance. Targeting exosome secretion could therefore potentially block these different processes. In this review, we will summarize the current findings of exosome-related processes in the BM and describe not only the current treatment strategies to counter them but also how exosomes can be harnessed to deliver toxic payloads. Finally, an overview of the different clinical studies that investigate EV cargo as potential MM biomarkers in liquid biopsies will be discussed.
Physical separation of haplotypes in dikaryons allows benchmarking of phasing accuracy in Nanopore and HiFi assemblies with Hi-C data
Authors: Hongyu Duan, Ashley W. Jones, Tim Hewitt, Amy Mackenzie, Yiheng Hu, Anna Sharp, David Lewis, Rohit Mago, Narayana M. Upadhyaya, John P. Rathjen, Eric A. Stone, Benjamin Schwessinger, Melania Figueroa, Peter N. Dodds, Sambasivam Periyannan, Jana Sperschneider
Journal: Genome biology (2022)

Abstract Background Most animals and plants have more than one set of chromosomes and package these haplotypes into a single nucleus within each cell. In contrast, many fungal species carry multiple haploid nuclei per cell. Rust fungi are such species with two nuclei (karyons) that contain a full set of haploid chromosomes each. The physical separation of haplotypes in dikaryons means that, unlike in diploids, Hi-C chromatin contacts between haplotypes are false-positive signals. Results We generate the first chromosome-scale, fully-phased assembly for the dikaryotic leaf rust fungus Puccinia triticina and compare Nanopore MinION and PacBio HiFi sequence-based assemblies. We show that false-positive Hi-C contacts between haplotypes are predominantly caused by phase switches rather than by collapsed regions or Hi-C read mis-mappings. We introduce a method for phasing of dikaryotic genomes into the two haplotypes using Hi-C contact graphs, including a phase switch correction step. In the HiFi assembly, relatively few phase switches occur, and these are predominantly located at haplotig boundaries and can be readily corrected. In contrast, phase switches are widespread throughout the Nanopore assembly. We show that haploid genome read coverage of 30–40 times using HiFi sequencing is required for phasing of the leaf rust genome, with 0.7% heterozygosity, and that HiFi sequencing resolves genomic regions with low heterozygosity that are otherwise collapsed in the Nanopore assembly. Conclusions This first Hi-C based phasing pipeline for dikaryons and comparison of long-read sequencing technologies will inform future genome assembly and haplotype phasing projects in other non-haploid organisms.
DETECTION OF CARDIAC AMYLOIDOSIS IN PATIENTS WITH SYSTEMIC AL AND ATTR AMYLOIDOSIS USING IODINE EVUZAMITIDE PET/CT IMAGING AND THE CORRELATION WITH SERUM NT-PROBNP
Authors: Jonathan Wall, R. Eric Heidel, Emily B. Martin, Alan Stuckey, Dustin Powell, Spencer Guthrie, Ronald Lands, Stephen J. Kennel
Journal: Journal of the American College of Cardiology (2022)
DUAL CHAMBER IMPLANTABLE CARDIOVERTER DEFIBRILLATOR PERFORATING ACROSS INTERVENTRICULAR SEPTUM IN THE ACUTE PERIOD FOLLOWING ANTERIOR MYOCARDIAL INFARCTION
Authors: Luke Soliman, Mohammad Saud Khan, Sameer Saleem, Travis R. Huffman, Sajjad Haider, Mohammed Kazimuddin
Journal: Journal of the American College of Cardiology (2022)
NATIONWIDE TRENDS OF BALLOON PULMONARY ANGIOPLASTY AND PULMONARY THROMBOENDARTERECTOMY FOR CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
Authors: Adam Vohra, Danielle A. Olonoff, Ada Ip, Evelyn M. Horn, Udhay Krishnan, Mark Reisman, Geoffrey Bergman, Shing-Chiu Wong, Dmitriy N. Feldman, Luke Kim, Harsimran S. Singh
Journal: Journal of the American College of Cardiology (2022)